Latigo Biotherapeutics Inc. (NASDAQ: LTGO) Stock Competitors & Peer Comparison
See LTGO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LTGO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LTGO | $22.37 | +4.53% | 1.3B | N/A | N/A | N/A |
| RPRX | $61.31 | +1.21% | 27.2B | 11.68 | $5.25 | +1.50% |
| CORT | $122.25 | +2.71% | 13.1B | 345.86 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $68.62 | -3.42% | 6.1B | 490.14 | $0.14 | N/A |
| KNSA | $79.03 | +0.71% | 6B | 87.81 | $0.90 | N/A |
| PBH | $51.31 | +1.56% | 2.4B | 11.61 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| HELP | $12.59 | +0.96% | 780.4M | -3.02 | -$4.16 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
LTGO vs RPRX Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, RPRX has a market cap of 27.2B. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while RPRX trades at $61.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 11.68. In terms of profitability, LTGO's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, LTGO is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
LTGO vs CORT Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, CORT has a market cap of 13.1B. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while CORT trades at $122.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 345.86. In terms of profitability, LTGO's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, LTGO is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
LTGO vs WBA Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, LTGO's ROE is N/A, compared to WBA's ROE of -0.42%. Regarding short-term risk, LTGO is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
LTGO vs LQDA Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, LQDA has a market cap of 6.1B. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while LQDA trades at $68.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 490.14. In terms of profitability, LTGO's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, LTGO is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
LTGO vs KNSA Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while KNSA trades at $79.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 87.81. In terms of profitability, LTGO's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, LTGO is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check KNSA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
LTGO vs PBH Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while PBH trades at $51.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas PBH's P/E ratio is 11.61. In terms of profitability, LTGO's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, LTGO is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
LTGO vs HROWL Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, LTGO is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
LTGO vs HROWM Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas HROWM's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, LTGO is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HROWM's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
LTGO vs HELP Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, HELP has a market cap of 780.4M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while HELP trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas HELP's P/E ratio is -3.02. In terms of profitability, LTGO's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, LTGO is more volatile compared to HELP. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
LTGO vs SVA Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas SVA's P/E ratio is -5.68. In terms of profitability, LTGO's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, LTGO is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
LTGO vs CUVL Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, CUVL has a market cap of 390.3M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while CUVL trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
LTGO vs HITI Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, HITI has a market cap of 215.3M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while HITI trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas HITI's P/E ratio is 61.25. In terms of profitability, LTGO's ROE is N/A, compared to HITI's ROE of -0.43%. Regarding short-term risk, LTGO is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
LTGO vs CELG-RI Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to CELG-RI's ROE of N/A. Regarding short-term risk, LTGO is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check CELG-RI's competition here
Atlantic International Corp. (NASDAQ: ATLN)
LTGO vs ATLN Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -0.68. In terms of profitability, LTGO's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, LTGO is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
LTGO vs CTOR Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while CTOR trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -1.62. In terms of profitability, LTGO's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, LTGO is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CTOR's competition here
Stablecoin Development Corp. (AMEX: SDEV)
LTGO vs SDEV Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, SDEV has a market cap of 57M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while SDEV trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.20. In terms of profitability, LTGO's ROE is N/A, compared to SDEV's ROE of +7.90%. Regarding short-term risk, LTGO is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
LTGO vs RAD Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, LTGO's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, LTGO is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
LTGO vs GLTO Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, LTGO's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, LTGO is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
LTGO vs NSRX Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, NSRX has a market cap of 34.5M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while NSRX trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -5.56. In terms of profitability, LTGO's ROE is N/A, compared to NSRX's ROE of +0.00%. Regarding short-term risk, LTGO is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
LTGO vs SCYX Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, SCYX has a market cap of 32.1M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while SCYX trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.49. In terms of profitability, LTGO's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, LTGO is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SCYX's competition here
Cerenome, Inc. (NASDAQ: CNSY)
LTGO vs CNSY Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, CNSY has a market cap of 20.6M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while CNSY trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.42. In terms of profitability, LTGO's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, LTGO is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
LTGO vs BFRI Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, BFRI has a market cap of 18.9M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while BFRI trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -2.69. In terms of profitability, LTGO's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, LTGO is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BFRI's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
LTGO vs BFRIW Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, BFRIW has a market cap of 16.7M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, LTGO's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, LTGO is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
LTGO vs COSM Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, COSM has a market cap of 11.6M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while COSM trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.29. In terms of profitability, LTGO's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, LTGO is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check COSM's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
LTGO vs CJJD Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, LTGO's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, LTGO is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
LTGO vs SSY Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, LTGO's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, LTGO is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
LTGO vs POM Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, POM has a market cap of 6.5M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while POM trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.19. In terms of profitability, LTGO's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, LTGO is more volatile compared to POM. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
LTGO vs BGMS Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while BGMS trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.25. In terms of profitability, LTGO's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, LTGO is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
LTGO vs PAVS Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, PAVS has a market cap of 4.3M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while PAVS trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.06. In terms of profitability, LTGO's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, LTGO is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
LTGO vs MDVL Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, LTGO's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, LTGO is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
LTGO vs ATNFW Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, LTGO is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
LTGO vs BGMSP Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, LTGO's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, LTGO is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
LTGO vs AZNH Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, LTGO's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, LTGO is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check AZNH's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
LTGO vs PRPH Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, PRPH has a market cap of 346.2K. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while PRPH trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas PRPH's P/E ratio is -0.01. In terms of profitability, LTGO's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, LTGO is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check PRPH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
LTGO vs LFLYW Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, LTGO's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, LTGO is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check LFLYW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
LTGO vs ESRX Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, LTGO's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, LTGO is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check ESRX's competition here
POZEN Inc. (NASDAQ: POZN)
LTGO vs POZN Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, POZN has a market cap of 0. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, LTGO is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check POZN's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
LTGO vs CPD Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, CPD has a market cap of 0. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, LTGO's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, LTGO is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check CPD's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
LTGO vs IPXL Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, LTGO's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, LTGO is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check IPXL's competition here
Shire plc (NASDAQ: SHPG)
LTGO vs SHPG Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, LTGO's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, LTGO is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for LTGO.Check SHPG's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
LTGO vs OREX Comparison August 2026
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LTGO stands at 1.3B. In comparison, OREX has a market cap of 0. Regarding current trading prices, LTGO is priced at $22.37 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LTGO currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, LTGO's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, LTGO is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for LTGO.Check OREX's competition here